182,992 Shares in Harvard Bioscience, Inc. $HBIO Bought by Meros Investment Management LP

Meros Investment Management LP bought a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401,000. Meros Investment Management LP owned about 4.02% of Harvard Bioscience as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Bank of America Corp DE raised its stake in Harvard Bioscience by 44.4% during the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Harvard Bioscience by 7.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock valued at $606,000 after acquiring an additional 78,276 shares in the last quarter. Strs Ohio bought a new position in Harvard Bioscience during the first quarter worth $117,000. Marshall Wace LLP bought a new position in Harvard Bioscience during the second quarter worth $61,000. Finally, Jane Street Group LLC boosted its holdings in Harvard Bioscience by 491.9% in the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 58,785 shares during the period. Institutional investors and hedge funds own 80.87% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HBIO. Benchmark increased their target price on shares of Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a report on Wednesday, August 12th. Weiss Ratings lowered shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Harvard Bioscience has an average rating of “Hold” and a consensus target price of $6.75.

Harvard Bioscience Stock Performance

HBIO opened at $7.58 on Wednesday. The company has a current ratio of 1.87, a quick ratio of 0.98 and a debt-to-equity ratio of 4.94. The business’s 50 day moving average is $6.31 and its 200-day moving average is $5.92. The stock has a market cap of $34.49 million, a PE ratio of -3.28 and a beta of 1.49. Harvard Bioscience, Inc. has a twelve month low of $3.75 and a twelve month high of $9.40.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%.The firm had revenue of $22.73 million for the quarter, compared to analysts’ expectations of $21.45 million.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.